Clareo Health | A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of moderate to severe Rheumatoid Arthritis (RA) according to the investigator.
Decision to initiate UPA treatment by investigator according to the local product label independent of the participant's participation in the study.
Has been previously treated with Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and corresponds to one of the following subgroups:
* Has not been previously exposed to any Biologic Disease-Modifying Antirheumatic Drugs (bDMARD) or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (tsDMARD).
* Has not been previously exposed to tsDMARD and has been previously exposed to \<= 2 bDMARDs.
* Has been previously treated with one tsDMARD and \<=1 bDMARD prior to treatment with that tsDMARD.
You may not be if
Presence of any condition that, in the opinion of the treating physician, prohibits the participant from participating in the study or obscures the assessment of the treatment of RA.
Diagnosis of rheumatic disease other than RA.
Diagnosis of juvenile RA.
Currently participating in an investigational clinical trial.
Has prior exposure to a bDMARD after exposure to a tsDMARD.
Has prior exposure to tsDMARD in an investigational clinical trial.
